

Please amend the application as follows:

IN THE CLAIMS

Please cancel claims 1-11, 12-13, 21-26, and 27, without prejudice.

REMARKS

In response to a Restriction Requirement, applicants hereby elect the Group III claims, i.e., claims 14-20 and 28, which the Examiner states read on methods employing agents which inhibit Smad-1 or Smad-5 phosphorylation. The Examiner also requires that a single species of agent which inhibits smad phosphorylation be elected with the election of Group III. Applicants hereby elect an antibody which binds to TGF- β .

Applicants have canceled non-elected claims 1-11, 12-13, 21-26, and 27 without prejudice and expressly reserve the right to pursue the subject matter of the non-elected claims in subsequent applications.

No fee is believed to be due, however, should a fee become due the Commissioner is hereby authorized to deduct any fee associated with this filing from Deposit Account No. 500624.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By Mary Anne Schofield
Mary Anne Schofield
Reg No. 36,669

666 Fifth Avenue
New York, N.Y. 10103
(212) 318-3000